BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next?

BioLineRx Ltd. (NASDAQ:BLRX) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.88 and traded as high as $3.37. BioLineRx shares last traded at $3.16, with a volume of 60,317 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioLineRx in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

BioLineRx Trading Up 3.3%

The company has a fifty day simple moving average of $2.60 and a two-hundred day simple moving average of $2.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.95 and a quick ratio of 1.78. The company has a market capitalization of $13.75 million, a P/E ratio of -18.59 and a beta of 1.42.

BioLineRx (NASDAQ:BLRX) last posted its earnings results on Tuesday, March 24th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.16. BioLineRx had a negative return on equity of 5.61% and a negative net margin of 99.58%.The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.49 million.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.